Submit Deal

SAGE THERAPEUTICS

HQ - Cambridge

Summary

Sage Therapeutics, Inc. develops treatments for central nervous system disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Sage Therapeutics operates in the United States.

Deals Overview

Total Deals2

Valued Deals2

Total Value£ 1.45 B

Avg. Deal Size£ 725 M

Market Context

Senior Management

Barry Greene
CEO
Ashley Kaplowitz
Vice President, Investor Relations & Capital Markets
Jeff Boyle
Investors Relations Director

Sort

barry greene

CEO at SAGE THERAPEUTICS

Manager

Deal

£ 325 M

Total Value

jeff boyle

Investors Relations Director at SAGE THERAPEUTICS

Manager

Deal

£ 1.13 B

Total Value

ashley kaplowitz

Vice President, Investor Relations & Capital Markets at SAGE THERAPEUTICS

Manager

Deal

£ 325 M

Total Value

maureen l. suda

Communications Director at SAGE THERAPEUTICS

Manager

Deal

£ 1.13 B

Total Value

mike cloonan

COO at SAGE THERAPEUTICS

Manager

Deal

£ 1.13 B

Total Value

francesca dellelci

Executive Director, Corporate Communications at SAGE THERAPEUTICS

Manager

Deal

£ 325 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy